Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemifloxacin-based Regimen for Helicobacter Pylori Infection
NCT02368470Phase 3Unknown
- Sponsor
- Samsung Medical Center
- Start
- Feb 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemifloxacin in Helicobacter pylori infection (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Helicobacter pylori eradication rate up to 10 months. Status: unknown.
02
Drugs
gemifloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT02368470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02368470.